Information Provided By:
Fly News Breaks for January 19, 2016
MDVN
Jan 19, 2016 | 08:44 EDT
Brean Capital lowered its price target on Medivation to $61 from $71 but still sees substantial upside from its current valuation. The firm noted the company increased its salesforce and divided it into an oncology team and a urology team, which should raise its awareness among doctors. Brean Capital reiterate its Buy rating on Medivation shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN